Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Arbutus reports $2.25B Moderna settlement and progress in hepatitis B cure trials
MRNA
$66.96
-$0.48 -0.71%

Arbutus reports $2.25B Moderna settlement and progress in hepatitis B cure trials

Company Fundamentals
23 Mar 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Arbutus Biopharma announced a $2.25 billion global settlement with Moderna over lipid nanoparticle patent infringement, including $950 million upfront and $1.3 billion contingent on an appellate ruling. The company also reported positive clinical trial results, with two additional patients achieving functional cure in its Phase 2a hepatitis B treatment trials, totaling 10 cured patients. Financially, Arbutus ended 2025 with $91.5 million in cash and investments, reduced operating expenses, and a net loss of $33.5 million. The company plans a potential return of capital to shareholders in Q3 2026 following receipt of settlement payments.

More News (MRNA)

Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.

Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.

Moderna is set to report its Q2 results on July 31, with expectations of a modest revenue decline due to seasonal COVID-19 vaccine demand. Jefferies forecasts a loss of $1.99 per share on about $100 million revenue, down from Q1's $389 million. Inves...

Company Fundamentals
Neutral
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App